Lawrence A Loeb

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/618008/publications.pdf Version: 2024-02-01

	13865	16650
17,505	67	123
citations	h-index	g-index
223	223	16538
docs citations	times ranked	citing authors
	citations 223	17,505 67 citations h-index 223 223

LAWDENCE A LOER

#	Article	IF	CITATIONS
1	Accurate detection of subclonal variants in paired diagnosis-relapse acute myeloid leukemia samples by next generation Duplex Sequencing. Leukemia Research, 2022, 115, 106822.	0.8	2
2	Rare Mutations in Cancer Drug Resistance and Implications for Therapy. Clinical Pharmacology and Therapeutics, 2020, 108, 437-439.	4.7	13
3	Co-Occurring Mutation Clusters Predict Drug Sensitivity in Acute Myeloid Leukemia. Blood, 2020, 136, 12-13.	1.4	1
4	Ultra-Sensitive TP53 Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue over a Century of Human Lifespan. Cell Reports, 2019, 28, 132-144.e3.	6.4	72
5	A high-resolution landscape of mutations in the <i>BCL6</i> super-enhancer in normal human B cells. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 24779-24785.	7.1	17
6	Extensive subclonal mutational diversity in human colorectal cancer and its significance. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26863-26872.	7.1	44
7	Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nature Reviews Genetics, 2018, 19, 269-285.	16.3	374
8	Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clinical Cancer Research, 2018, 24, 5321-5334.	7.0	24
9	High Throughput Drug Screening of Leukemia Stem Cells Reveals Resistance to Standard Therapies and Sensitivity to Other Agents in Acute Myeloid Leukemia. Blood, 2018, 132, 180-180.	1.4	5
10	Evolutionary dynamics and significance of multiple subclonal mutations in cancer. DNA Repair, 2017, 56, 7-15.	2.8	16
11	Richmond T. Prehn: In Memoriam (1922–2016). Cancer Research, 2017, 77, 593-594.	0.9	0
12	Mutational spectra of aflatoxin B ₁ in vivo establish biomarkers of exposure for human hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E3101-E3109.	7.1	100
13	Homozygosity for the WRN Helicase-Inactivating Variant, R834C, does not confer a Werner syndrome clinical phenotype. Scientific Reports, 2017, 7, 44081.	3.3	12
14	Accurate RNA consensus sequencing for high-fidelity detection of transcriptional mutagenesis-induced epimutations. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 9415-9420.	7.1	25
15	Decreased Mitochondrial Mutagenesis during Transformation of Human Breast Stem Cells into Tumorigenic Cells. Cancer Research, 2016, 76, 4569-4578.	0.9	19
16	Human Cancers Express a Mutator Phenotype: Hypothesis, Origin, and Consequences. Cancer Research, 2016, 76, 2057-2059.	0.9	84
17	Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic <i>TP53</i> mutations in noncancerous tissues. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6005-6010.	7.1	135
18	Why Cockayne syndrome patients do not get cancer despite their DNA repair deficiency. Proceedings of the United States of America, 2016, 113, 10151-10156.	7.1	39

#	Article	IF	CITATIONS
19	Exploring the implications of distinct mutational signatures and mutation rates in aging and cancer. Genome Medicine, 2016, 8, 30.	8.2	13
20	Tobacco Causes Human Cancers—A Concept Founded on Epidemiology and an Insightful Experiment Now Requires Translation Worldwide. Cancer Research, 2016, 76, 765-766.	0.9	5
21	The influence of subclonal resistance mutations on targeted cancer therapy. Nature Reviews Clinical Oncology, 2016, 13, 335-347.	27.6	185
22	Analysis of the Sub-Clonal Origins of Compound Mutations in Patients with Refractory Ph+ Malignancies Treated with Ponatinib. Blood, 2016, 128, 1061-1061.	1.4	1
23	Sequencing small genomic targets with high efficiency and extreme accuracy. Nature Methods, 2015, 12, 423-425.	19.0	128
24	Emergence of Sub-Clonal Drug Resistance Mutations during CML Therapy. Blood, 2015, 126, 478-478.	1.4	1
25	Detection of Ultra-Rare Mitochondrial Mutations in Breast Stem Cells by Duplex Sequencing. PLoS ONE, 2015, 10, e0136216.	2.5	41
26	Mutator Phenotype. , 2015, , 1-5.		0
27	Mutator Phenotype. , 2015, , 2965-2969.		0
28	Detecting ultralow-frequency mutations by Duplex Sequencing. Nature Protocols, 2014, 9, 2586-2606.	12.0	360
29	One cell at a time. Nature, 2014, 512, 143-144.	27.8	34
30	Sphingosine, a Modulator of Human Translesion DNA Polymerase Activity. Journal of Biological Chemistry, 2014, 289, 21663-21672.	3.4	9
31	A Rapid Assay for Measuring Nucleotide Excision Repair by Oligonucleotide Retrieval. Scientific Reports, 2014, 4, 4894.	3.3	24
32	Targeted Ultra-Deep High Accuracy Sequencing of Pre-Treatment AML Reveals a Diversity of Mutational Phenotypes and Evidence of Preexisting Relapse-Associated Subclones. Blood, 2014, 124, 2372-2372.	1.4	0
33	APOBEC3B mutagenesis in cancer. Nature Genetics, 2013, 45, 964-965.	21.4	89
34	Altered RECQ Helicase Expression in Sporadic Primary Colorectal Cancers. Translational Oncology, 2013, 6, 458-IN10.	3.7	40
35	An in-frame deletion at the polymerase active site of POLD1 causes a multisystem disorder with lipodystrophy. Nature Genetics, 2013, 45, 947-950.	21.4	151
36	Do mutator mutations fuel tumorigenesis?. Cancer and Metastasis Reviews, 2013, 32, 353-361.	5.9	64

#	Article	IF	CITATIONS
37	Ultra-Sensitive Sequencing Reveals an Age-Related Increase in Somatic Mitochondrial Mutations That Are Inconsistent with Oxidative Damage. PLoS Genetics, 2013, 9, e1003794.	3.5	289
38	Clonal Expansions and Short Telomeres Are Associated with Neoplasia in Early-onset, but not Late-onset, Ulcerative Colitis. Inflammatory Bowel Diseases, 2013, 19, 2593-2602.	1.9	23
39	A Substitution in the Fingers Domain of DNA Polymerase δ Reduces Fidelity by Altering Nucleotide Discrimination in the Catalytic Site*. Journal of Biological Chemistry, 2013, 288, 5572-5580.	3.4	15
40	The Werner Syndrome Exonuclease Facilitates DNA Degradation and High Fidelity DNA Polymerization by Human DNA Polymerase Î*. Journal of Biological Chemistry, 2012, 287, 12480-12490.	3.4	40
41	Implications of genetic heterogeneity in cancer. Annals of the New York Academy of Sciences, 2012, 1267, 110-116.	3.8	59
42	DNA polymerase delta in dna replication and genome maintenance. Environmental and Molecular Mutagenesis, 2012, 53, 666-682.	2.2	103
43	Detection of ultra-rare mutations by next-generation sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14508-14513.	7.1	840
44	Somatic mutations in aging, cancer and neurodegeneration. Mechanisms of Ageing and Development, 2012, 133, 118-126.	4.6	180
45	The Werner Syndrome Protein Is Distinguished from the Bloom Syndrome Protein by Its Capacity to Tightly Bind Diverse DNA Structures. PLoS ONE, 2012, 7, e30189.	2.5	42
46	The Biochemistry and Fidelity of Synthesis by the Apicoplast Genome Replication DNA Polymerase Pfprex from the Malaria Parasite Plasmodium falciparum. Journal of Molecular Biology, 2011, 410, 27-38.	4.2	15
47	Mutation of HIV-1 Genomes in a Clinical Population Treated with the Mutagenic Nucleoside KP1461. PLoS ONE, 2011, 6, e15135.	2.5	71
48	Human cancers express mutator phenotypes: origin, consequences and targeting. Nature Reviews Cancer, 2011, 11, 450-457.	28.4	342
49	XPG and WRN: An unexpected partnership. Cell Cycle, 2011, 10, 3051-3051.	2.6	0
50	Roles of DNA polymerase I in leading and lagging-strand replication defined by a high-resolution mutation footprint of ColE1 plasmid replication. Nucleic Acids Research, 2011, 39, 7020-7033.	14.5	25
51	A random mutation capture assay to detect genomic point mutations in mouse tissue. Nucleic Acids Research, 2011, 39, e73-e73.	14.5	15
52	Mitochondrial mutagenesis induced by tumor-specific radiation bystander effects. Journal of Molecular Medicine, 2010, 88, 701-708.	3.9	15
53	Lethal Mutagenesis: Targeting the Mutator Phenotype in Cancer. Seminars in Cancer Biology, 2010, 20, 353-359.	9.6	68
54	Mutator phenotype in cancer: Origin and consequences. Seminars in Cancer Biology, 2010, 20, 279-280.	9.6	32

#	Article	IF	CITATIONS
55	Reply: Is there any genetic instability in human cancer?. DNA Repair, 2010, 9, 859-860.	2.8	10
56	A Mitochondrial view of aging, reactive oxygen species and metastatic cancer. Aging Cell, 2010, 9, 462-465.	6.7	31
57	Active Site Mutations in Mammalian DNA Polymerase Ĩ´Alter Accuracy and Replication Fork Progression. Journal of Biological Chemistry, 2010, 285, 32264-32272.	3.4	18
58	Optimization of DNA polymerase mutation rates during bacterial evolution. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1154-1159.	7.1	80
59	Mutational Heterogeneity in Human Cancers: Origin and Consequences. Annual Review of Pathology: Mechanisms of Disease, 2010, 5, 51-75.	22.4	210
60	Frameshift Mutagenesis and Microsatellite Instability Induced by Human Alkyladenine DNA Glycosylase. Molecular Cell, 2010, 37, 843-853.	9.7	50
61	The Mutator Phenotype in Cancer: Molecular Mechanisms and Targeting Strategies. Current Drug Targets, 2010, 11, 1296-1303.	2.1	43
62	Molecularly Evolved Thymidylate Synthase Inhibits 5-Fluorodeoxyuridine Toxicity in Human Hematopoietic Cells. Human Gene Therapy, 2009, 20, 1703-1707.	2.7	6
63	Cancer Genome Sequencing—An Interim Analysis. Cancer Research, 2009, 69, 4948-4950.	0.9	70
64	Clonal expansions in ulcerative colitis identify patients with neoplasia. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20871-20876.	7.1	58
65	Overexpression of Catalase Targeted to Mitochondria Attenuates Murine Cardiac Aging. Circulation, 2009, 119, 2789-2797.	1.6	414
66	High fidelity and lesion bypass capability of human DNA polymerase δ. Biochimie, 2009, 91, 1163-1172.	2.6	88
67	On Mitochondria, Mutations, and Methodology. Cell Metabolism, 2009, 10, 437.	16.2	18
68	DNA deletions and clonal mutations drive premature aging in mitochondrial mutator mice. Nature Genetics, 2008, 40, 392-394.	21.4	360
69	DNA polymerases and human disease. Nature Reviews Genetics, 2008, 9, 594-604.	16.3	257
70	Substrate binding pocket residues of human alkyladenine-DNA glycosylase critical for methylating agent survival. DNA Repair, 2008, 7, 1731-1745.	2.8	7
71	Cancers Exhibit a Mutator Phenotype: Clinical Implications. Cancer Research, 2008, 68, 3551-3557.	0.9	198
72	Advances in Chemical Carcinogenesis: A Historical Review and Prospective. Cancer Research, 2008, 68, 6863-6872.	0.9	258

#	Article	IF	CITATIONS
73	The Werner Syndrome Protein Binds Replication Fork and Holliday Junction DNAs as an Oligomer. Journal of Biological Chemistry, 2008, 283, 24478-24483.	3.4	64
74	Highly Tolerated Amino Acid Substitutions Increase the Fidelity of Escherichia coli DNA Polymerase I. Journal of Biological Chemistry, 2007, 282, 12201-12209.	3.4	44
75	Werner syndrome protein interacts functionally with translesion DNA polymerases. Proceedings of the United States of America, 2007, 104, 10394-10399.	7.1	54
76	Mutation at the Polymerase Active Site of Mouse DNA Polymerase δIncreases Genomic Instability and Accelerates Tumorigenesis. Molecular and Cellular Biology, 2007, 27, 7669-7682.	2.3	98
77	Genetic Constraints on Protein Evolution. Critical Reviews in Biochemistry and Molecular Biology, 2007, 42, 313-326.	5.2	121
78	Mitochondrial point mutations do not limit the natural lifespan of mice. Nature Genetics, 2007, 39, 540-543.	21.4	349
79	LOH-proficient embryonic stem cells: a model of cancer progenitor cells?. Trends in Genetics, 2007, 23, 154-157.	6.7	9
80	DNA Repair Enzymes. , 2006, , 179-196.		0
81	Mitochondrial DNA integrity is not dependent on DNA polymerase-β activity. DNA Repair, 2006, 5, 71-79.	2.8	26
82	Generation of mutator mutants during carcinogenesis. DNA Repair, 2006, 5, 294-302.	2.8	47
83	Mutations in DNA polymerase $\hat{\mathbf{l}}\cdot$ are not detected in squamous cell carcinoma of the skin. International Journal of Cancer, 2006, 119, 2225-2227.	5.1	9
84	Efficiency of carcinogenesis with and without a mutator mutation. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14140-14145.	7.1	89
85	Human cancers express a mutator phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18238-18242.	7.1	331
86	Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells. Molecular Cancer Therapeutics, 2006, 5, 121-128.	4.1	9
87	Mutator Phenotypes Caused by Substitution at a Conserved Motif A Residue in Eukaryotic DNA Polymerase l´. Journal of Biological Chemistry, 2006, 281, 4486-4494.	3.4	68
88	Quantification of random genomic mutations. Nature Methods, 2005, 2, 285-290.	19.0	90
89	Genetic instability in cancer: Theory and experiment. Seminars in Cancer Biology, 2005, 15, 423-435.	9.6	116
90	Incorporation of reporter-labeled nucleotides by DNA polymerases. BioTechniques, 2005, 38, 257-264.	1.8	59

#	Article	IF	CITATIONS
91	Negative Clonal Selection in Tumor Evolution. Genetics, 2005, 171, 2123-2131.	2.9	44
92	Mutability of DNA polymerase I: Implications for the creation of mutant DNA polymerases. DNA Repair, 2005, 4, 1390-1398.	2.8	42
93	Lethal mutagenesis of HIV. Virus Research, 2005, 107, 215-228.	2.2	55
94	The mitochondrial theory of aging and its relationship to reactive oxygen species damage and somatic mtDNA mutations. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18769-18770.	7.1	195
95	When Pol I Goes into High Gear: Processive DNA Synthesis by Pol I in the Cell. Cell Cycle, 2004, 3, 114-116.	2.6	46
96	Protein tolerance to random amino acid change. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9205-9210.	7.1	267
97	Mutations in the R2 Subunit of Ribonucleotide Reductase That Confer Resistance to Hydroxyurea. Journal of Biological Chemistry, 2004, 279, 40723-40728.	3.4	31
98	The Enzymatic Activities of the Werner Syndrome Protein Are Disabled by the Amino Acid Polymorphism R834C. Journal of Biological Chemistry, 2004, 279, 55499-55505.	3.4	49
99	Destabilization of tetraplex structures of the fragile X repeat sequence (CGG)n is mediated by homolog-conserved domains in three members of the hnRNP family. Nucleic Acids Research, 2004, 32, 4145-4154.	14.5	63
100	Mice and mitochondria. Nature, 2004, 429, 357-359.	27.8	28
101	Environmental and chemical carcinogenesis. Seminars in Cancer Biology, 2004, 14, 473-486.	9.6	522
102	Viral Error Catastrophe by Mutagenic Nucleosides. Annual Review of Microbiology, 2004, 58, 183-205.	7.3	198
103	The Werner syndrome protein confers resistance to the DNA lesions N3-methyladenine and O6-methylguanine: implications for WRN function. DNA Repair, 2004, 3, 629-638.	2.8	44
104	The N-terminal domain of the large subunit of human replication protein A binds to Werner syndrome protein and stimulates helicase activity. Mechanisms of Ageing and Development, 2003, 124, 921-930.	4.6	60
105	Multiple mutations and cancer. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 776-781.	7.1	657
106	Targeted gene evolution in Escherichia coli using a highly error-prone DNA polymerase I. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9727-9732.	7.1	141
107	Amino Acid Substitutions at Conserved Tyrosine 52 Alter Fidelity and Bypass Efficiency of Human DNA Polymerase Î. Journal of Biological Chemistry, 2003, 278, 19341-19346.	3.4	16
108	Mutations in the α8 Loop of Human APE1 Alter Binding and Cleavage of DNA Containing an Abasic Site. Journal of Biological Chemistry, 2003, 278, 46994-47001.	3.4	13

#	Article	IF	CITATIONS
109	Insertion of the T3 DNA polymerase thioredoxin binding domain enhances the processivity and fidelity of Taq DNA polymerase. Nucleic Acids Research, 2003, 31, 4702-4709.	14.5	45
110	Tumbling down a different pathway to genetic instability. Journal of Clinical Investigation, 2003, 112, 1793-1795.	8.2	16
111	Targeted mutagenesis in E. coli: A powerful tool for the generation of random mutant libraries. Discovery Medicine, 2003, 3, 36-7.	0.5	2
112	The Processing of Holliday Junctions by BLM and WRN Helicases Is Regulated by p53. Journal of Biological Chemistry, 2002, 277, 31980-31987.	3.4	107
113	Distribution of Mutations in Human Thymidylate Synthase Yielding Resistance to 5-Fluorodeoxyuridine. Journal of Biological Chemistry, 2002, 277, 36304-36311.	3.4	41
114	In Vitro Production and Screening of DNA Polymerase η Mutants for Catalytic Diversity. BioTechniques, 2002, 33, 1136-1144.	1.8	11
115	Deregulated DNA polymerase beta induces chromosome instability and tumorigenesis. Cancer Research, 2002, 62, 3511-4.	0.9	95
116	Prokaryotic DNA polymerase I: evolution, structure, and "base flipping―mechanism for nucleotide selection. Journal of Molecular Biology, 2001, 308, 823-837.	4.2	182
117	Getting a grip on how DNA polymerases function. , 2001, 8, 656-659.		78
118	Unwinding the molecular basis of the Werner syndrome. Mechanisms of Ageing and Development, 2001, 122, 921-944.	4.6	100
119	A Single Highly Mutable Catalytic Site Amino Acid Is Critical for DNA Polymerase Fidelity. Journal of Biological Chemistry, 2001, 276, 5044-5051.	3.4	96
120	The Conserved Active Site Motif A of Escherichia coliDNA Polymerase I Is Highly Mutable. Journal of Biological Chemistry, 2001, 276, 18836-18842.	3.4	46
121	In Vivo Mutagenesis by Escherichia coliDNA Polymerase I. Journal of Biological Chemistry, 2001, 276, 46759-46764.	3.4	36
122	Interactions between the Werner Syndrome Helicase and DNA Polymerase I´ Specifically Facilitate Copying of Tetraplex and Hairpin Structures of the d(CGG) Trinucleotide Repeat Sequence. Journal of Biological Chemistry, 2001, 276, 16439-16446.	3.4	183
123	The Werner syndrome gene: the molecular basis of RecQ helicase-deficiency diseases. Trends in Genetics, 2000, 16, 213-220.	6.7	176
124	Enhanced in vivo repair of O4-methylthymine by a mutant human DNA alkyltransferase. Carcinogenesis, 2000, 21, 1397-1402.	2.8	0
125	Thermus aquaticus DNA Polymerase I Mutants with Altered Fidelity. Journal of Biological Chemistry, 2000, 275, 32728-32735.	3.4	69
126	Perspective - Lethal Mutagenesis of HIV by Mutagenic Ribonucleoside Analogs. AIDS Research and Human Retroviruses, 2000, 16, 1-3.	1.1	72

#	Article	IF	CITATIONS
127	Human Ku Antigen Tightly Binds and Stabilizes a Tetrahelical Form of the Fragile X Syndrome d(CGG) Expanded Sequence. Journal of Biological Chemistry, 2000, 275, 33134-33141.	3.4	26
128	Enhanced in vivo repair of O4 -methylthymine by a mutant human DNA alkyltransferase. Carcinogenesis, 2000, 21, 1397-1402.	2.8	8
129	Multiple Amino Acid Substitutions Allow DNA Polymerases to Synthesize RNA. Journal of Biological Chemistry, 2000, 275, 40266-40272.	3.4	94
130	Significance of multiple mutations in cancer. Carcinogenesis, 2000, 21, 379-385.	2.8	392
131	Human Werner Syndrome DNA Helicase Unwinds Tetrahelical Structures of the Fragile X Syndrome Repeat Sequence d(CGG). Journal of Biological Chemistry, 1999, 274, 12797-12802.	3.4	330
132	Human O6 -alkylguanine-DNA alkyltransferase: protection against alkylating agents and sensitization to dibromoalkanes. Carcinogenesis, 1999, 20, 2089-2094.	2.8	19
133	Improving enzymes for cancer gene therapy. Nature Biotechnology, 1999, 17, 143-147.	17.5	80
134	Redesigning the Substrate Specificity of HumanO6-Alkylguanine-DNA Alkyltransferase. Mutants with Enhanced Repair ofO4-Methylthymineâ€. Biochemistry, 1999, 38, 12097-12103.	2.5	22
135	Genetic Instability and the Mutator Phenotype. American Journal of Pathology, 1999, 154, 1621-1626.	3.8	68
136	The three faces of the WS helicase. Nature Genetics, 1998, 19, 308-309.	21.4	21
137	One small StEP in molecular evolution…. Nature Biotechnology, 1998, 16, 234-235.	17.5	1
138	Origin of Multiple Mutations in Human Cancers. Drug Metabolism Reviews, 1998, 30, 285-304.	3.6	8
139	Fidelity of Mutant HIV-1 Reverse Transcriptases:Â Interaction with the Single-Stranded Template Influences the Accuracy of DNA Synthesisâ€. Biochemistry, 1998, 37, 5831-5839.	2.5	45
140	Characterization of Werner syndrome protein DNA helicase activity: Directionality, substrate dependence and stimulation by replication protein A. Nucleic Acids Research, 1998, 26, 2879-2885.	14.5	208
141	Random Sequence Mutagenesis and Resistance to 5-Fluorouridine in Human Thymidylate Synthases. Journal of Biological Chemistry, 1998, 273, 25809-25817.	3.4	33
142	Werner Syndrome Protein. Journal of Biological Chemistry, 1998, 273, 34139-34144.	3.4	233
143	Werner Syndrome Protein. Journal of Biological Chemistry, 1998, 273, 34145-34150.	3.4	204
144	The Mutation Rate and Cancer. Genetics, 1998, 148, 1483-1490.	2.9	197

#	Article	IF	CITATIONS
145	Incorporation of the Guanosine Triphosphate Analogs 8-Oxo-dGTP and 8-NH2-dGTP by Reverse Transcriptases and Mammalian DNA Polymerases. Journal of Biological Chemistry, 1997, 272, 5892-5898.	3.4	76
146	Low Fidelity Mutants in the O-Helix of Thermus aquaticus DNA Polymerase I. Journal of Biological Chemistry, 1997, 272, 11228-11235.	3.4	66
147	The Werner syndrome protein is a DNA helicase. Nature Genetics, 1997, 17, 100-103.	21.4	594
148	Inefficient Repair of RNA . DNA Hybrids. FEBS Journal, 1997, 250, 492-501.	0.2	19
149	Creating novel enzymes by applied molecular evolution. Chemistry and Biology, 1997, 4, 889-898.	6.0	36
150	Unnatural Nucleotide Sequences in Biopharmaceutics. Advances in Pharmacology, 1996, 35, 321-347.	2.0	5
151	OXIDANTS AND MULTIPLE MUTATIONS IN CANCER. Biochemical Society Transactions, 1996, 24, 522S-522S.	3.4	0
152	Tolerance of different proteins for amino acid diversity. Molecular Diversity, 1996, 2, 111-118.	3.9	27
153	Human Immunodeficiency Virus Reverse Transcriptase. Journal of Biological Chemistry, 1996, 271, 4872-4878.	3.4	55
154	Mutagenicity and pausing of HIV reverse transcriptase during HIV plus-strand DNA synthesis. Nucleic Acids Research, 1994, 22, 47-52.	14.5	50
155	Herpes thymidine kinase mutants with altered catalytic efficiencies obtained by random sequence selection. Protein Engineering, Design and Selection, 1994, 7, 83-89.	2.1	20
156	Evidence against DNA polymerase ? as a candidate gene for Werner syndrome. Human Genetics, 1994, 93, 507-12.	3.8	7
157	Oxygen radical induced mutagenesis is DNA polymerase specific. Journal of Molecular Biology, 1994, 235, 33-41.	4.2	61
158	Selection of new biologically active molecules from random nucleotide sequences. Gene, 1993, 137, 41-47.	2.2	15
159	Multi-stage proofreading in DNA replication. Quarterly Reviews of Biophysics, 1993, 26, 225-331.	5.7	55
160	DNA damage and repair in brain: relationship to aging. Mutation Research - DNAging, 1992, 275, 317-329.	3.2	39
161	The association of thymidine kinase activity and thymidine transport in Escherichia coli. Gene, 1991, 99, 25-29.	2.2	12
162	Errors in DNA synthesis: A source of spontaneous mutations. Mutation Research - Reviews in Genetic Toxicology, 1990, 238, 297-304.	2.9	56

#	Article	IF	CITATIONS
163	Innovative funding for cancer research: California's antismoking initiative. Molecular Carcinogenesis, 1990, 3, 323-324.	2.7	0
164	Animal cell DNA polymerases in DNA repair. Mutation Research DNA Repair, 1990, 236, 289-300.	3.7	38
165	Structure?Function Relationships in Escherichia coli Promoter DNA. Progress in Molecular Biology and Translational Science, 1990, 38, 137-164.	1.9	19
166	Sequence specificity of pausing by DNA polymerases. Biochemical and Biophysical Research Communications, 1989, 164, 1149-1156.	2.1	20
167	On the fidelity of DNA replication: herpes DNA potymerase and its associated exonuclease. Nucleic Acids Research, 1987, 15, 1185-1198.	14.5	19
168	Aphidicolin-resistant mutator strains of mouse teratocarcinoma. Molecular Genetics and Genomics, 1987, 208, 342-348.	2.4	4
169	DNA Polymerase-α: Enzymology, Function, Fidelity, and Mutagenesis. Progress in Molecular Biology and Translational Science, 1986, 33, 57-110.	1.9	28
170	Controversies in the Basic Sciences: Is There an Inducible Error-Prone Pathway in Mammalian Cells That Is Responsible for Mutations by Many Chemical Carcinogens?. Cancer Investigation, 1985, 3, 161-161.	1.3	0
171	Fidelity of DNA Polymerase-? in Neurons from Young and Very Aged Mice. Journal of Neurochemistry, 1985, 45, 1273-1278.	3.9	23
172	Multipotent mutator strain of mouse teratocarcinoma cells. Somatic Cell and Molecular Genetics, 1985, 11, 211-216.	0.7	6
173	DNA polymerase \hat{I}_{\pm} and models for proofreading. Nucleic Acids Research, 1985, 13, 261-274.	14.5	23
174	Apurinic sites as mutagenic intermediates. Cell, 1985, 40, 483-484.	28.9	307
175	Site specific mutagenesis: insertion of single noncomplementary nucleotides at specified sites by error-directed DNA polymerization. Nucleic Acids Research, 1984, 12, 6615-6628.	14.5	14
176	Delayed and reduced cell replication and diminishing levels of DNA polymerase-? in regenerating liver of aging mice. Journal of Cellular Physiology, 1984, 118, 225-232.	4.1	83
177	Assessment of the carcinogenic potential of a proposed food coloring additive, laccaic acid, using short-term assays. Cell Biology and Toxicology, 1984, 1, 111-125.	5.3	6
178	UV irradiation alters deoxynucleoside triphosphate pools in Escherichia coli. Mutation Research - DNA Repair Reports, 1984, 131, 97-100.	1.8	17
179	Mouse teratocarcinoma cells resistant to aphidicolin and arabinofuranosyl cytosine: Isolation and initial characterization. Journal of Cellular Physiology, 1983, 115, 9-14.	4.1	3
180	Rapid changes in deoxynucleoside triphosphate pools in mammalian cells treated with mutagens. Biochemical and Biophysical Research Communications, 1983, 114, 458-464.	2.1	63

#	Article	IF	CITATIONS
181	Molecular Biology and Malignancy: Series Introduction Mechanisms of Neoplastic Transformation. Cancer Investigation, 1983, 1, 175-183.	1.3	7
182	Tumor Promoters: An Editorial Comment. Cancer Investigation, 1983, 1, 423-423.	1.3	1
183	Heat mutagenesis of bacteriophage φX174 in SOS-induced bacteria. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1982, 104, 75-78.	1.1	1
184	Site-specific mutagenesis by error-directed DNA synthesis. Nature, 1982, 295, 708-710.	27.8	39
185	On the activity and fidelity of chromatin-associated hepatic DNA polymerase-? in aging murine species of different life spans. Journal of Cellular Physiology, 1981, 106, 435-444.	4.1	36
186	Mutagenesis in vitro by depurination of $\hat{1}$ X174 DNA. Nature, 1981, 291, 349-351.	27.8	64
187	On the fidelity of DNA synthesis: Effects of steroids and intercalating agents. Chemico-Biological Interactions, 1980, 30, 1-8.	4.0	5
188	The Role of Metal Ions in the Mechanisms of DNA and RNA Polymerase. CRC Critical Reviews in Biochemistry, 1979, 6, 219-244.	2.0	108
189	Mutagenesis in vitro by DNA polymerase from an RNA tumour virus. Nature, 1979, 278, 857-859.	27.8	89
190	Effects of depurination on the fidelity of DNA synthesis. Journal of Molecular Biology, 1979, 128, 197-218.	4.2	82
191	Dna replication in human lymphocytes during aging. Journal of Cellular Physiology, 1978, 96, 235-243.	4.1	32
192	Depurination decreases fidelity of DNA synthesis in vitro. Nature, 1977, 270, 537-538.	27.8	47
193	Template recognition and chain elongation in DNA synthesis in vitro. Journal of Molecular Biology, 1976, 106, 605-621.	4.2	13
194	Metal activation of DNA synthesis. Biochemical and Biophysical Research Communications, 1976, 70, 812-817.	2.1	77
195	On the fidelity of transcription by Escherichia coli ribonucleic acid polymerase. Journal of Molecular Biology, 1975, 97, 577-591.	4.2	80
196	Manganese as a mutagenic agent during in vitro DNA synthesis. Biochemical and Biophysical Research Communications, 1975, 67, 1041-1046.	2.1	43
197	Erroneous base-pairing induced by a chemical carcinogen during DNA synthesis. Nature, 1974, 252, 414-416.	27.8	36
198	Zinc in reverse transcriptase. Biochemical and Biophysical Research Communications, 1974, 56, 959-964.	2.1	49

#	Article	IF	CITATIONS
199	Infidelity of DNA synthesis: A general property of RNA tumor viruses. Biochemical and Biophysical Research Communications, 1974, 61, 410-414.	2.1	21
200	[7] Sea urchin nuclear DNA polymerasel. Methods in Enzymology, 1974, 29, 53-70.	1.0	71
201	6. Eucaryotic DNA Polymerases. The Enzymes, 1974, 10, 173-209.	1.7	49
202	MULTIPLE DNA POLYMERASES. DISPLAYED BY ISOELECTRIC FOCUSING. Annals of the New York Academy of Sciences, 1973, 209, 354-362.	3.8	12
203	Infidelity of DNA synthesis by reverse transcriptase. Biochemical and Biophysical Research Communications, 1973, 52, 401-406.	2.1	28
204	Methylation of transfer RNA during transformation of human lymphocytes by phytohemagglutinin. Biochemical and Biophysical Research Communications, 1973, 50, 172-178.	2.1	13
205	Copying Natural RNAs with E. coli DNA Polymerase I. Nature: New Biology, 1973, 242, 66-69.	4.5	76
206	ZINC REQUIREMENT FOR DNA REPLICATION IN STIMULATED HUMAN LYMPHOCYTES. Journal of Cell Biology, 1973, 58, 594-601.	5.2	120
207	RNA-dependent DNA polymerase: Presence in normal human cells. Biochemical and Biophysical Research Communications, 1971, 42, 1228-1234.	2.1	39
208	In vitro DNA synthesis in the presence of antibody to homogeneous E. Coli DNA polymerase. Biochemical and Biophysical Research Communications, 1971, 42, 147-153.	2.1	10
209	ZINC in DNA polymerases. Biochemical and Biophysical Research Communications, 1971, 44, 37-43.	2.1	252
210	RNA-dependent DNA Polymerase in Human Lymphocytes during Gene Activation by Phytohaemagglutinin. Nature: New Biology, 1971, 232, 58-61.	4.5	32
211	Induction of DNA Polymerase in Mixed Lymphocyte Cultures. Nature, 1970, 226, 949-950.	27.8	2
212	AUSTRALIA ANTIGEN (A HEPATITIS-ASSOCIATED ANTIGEN). Journal of Experimental Medicine, 1970, 131, 1190-1199.	8.5	81
213	Structure of Drosophila melanogaster dAT replicated in an in vitro system. Biochemical and Biophysical Research Communications, 1970, 40, 1266-1272.	2.1	33
214	Initiation of DNA synthesis in eucaryotes: A model in vitro system. Biochemical and Biophysical Research Communications, 1970, 41, 589-593.	2.1	8
215	DNA polymerase activity as an index of lymphocyte stimulation: studies in Down's syndrome. Journal of Clinical Investigation, 1970, 49, 161-169.	8.2	72
216	Stimulation of Ammo-acid Incorporation by Nuclear Ribonucleic Acid from Normal and Methylcholanthrene-treated Rats. Nature, 1963, 199, 809-810.	27.8	25

#	Article	IF	CITATIONS
217	Applied Molecular Evolution of Enzymes Involved in Synthesis and Repair of DNA. , 0, , 281-307.		4